S&P 500   4,349.93 (-0.15%)
DOW   34,168.09 (-0.38%)
QQQ   344.57 (-0.16%)
AAPL   159.69 (-0.06%)
MSFT   296.71 (+2.85%)
FB   294.63 (-1.84%)
GOOGL   2,584.66 (+1.81%)
AMZN   2,777.45 (-0.80%)
TSLA   937.41 (+2.07%)
NVDA   227.72 (+2.01%)
BABA   113.37 (-4.84%)
NIO   22.66 (-4.75%)
AMD   110.71 (-0.38%)
CGC   7.23 (-1.77%)
MU   81.97 (+1.55%)
GE   89.32 (-1.96%)
T   24.25 (-8.42%)
F   19.91 (-0.35%)
DIS   133.60 (-2.13%)
AMC   15.94 (-0.50%)
PFE   53.01 (+0.89%)
ACB   4.06 (-3.56%)
BA   194.27 (-4.82%)
S&P 500   4,349.93 (-0.15%)
DOW   34,168.09 (-0.38%)
QQQ   344.57 (-0.16%)
AAPL   159.69 (-0.06%)
MSFT   296.71 (+2.85%)
FB   294.63 (-1.84%)
GOOGL   2,584.66 (+1.81%)
AMZN   2,777.45 (-0.80%)
TSLA   937.41 (+2.07%)
NVDA   227.72 (+2.01%)
BABA   113.37 (-4.84%)
NIO   22.66 (-4.75%)
AMD   110.71 (-0.38%)
CGC   7.23 (-1.77%)
MU   81.97 (+1.55%)
GE   89.32 (-1.96%)
T   24.25 (-8.42%)
F   19.91 (-0.35%)
DIS   133.60 (-2.13%)
AMC   15.94 (-0.50%)
PFE   53.01 (+0.89%)
ACB   4.06 (-3.56%)
BA   194.27 (-4.82%)
S&P 500   4,349.93 (-0.15%)
DOW   34,168.09 (-0.38%)
QQQ   344.57 (-0.16%)
AAPL   159.69 (-0.06%)
MSFT   296.71 (+2.85%)
FB   294.63 (-1.84%)
GOOGL   2,584.66 (+1.81%)
AMZN   2,777.45 (-0.80%)
TSLA   937.41 (+2.07%)
NVDA   227.72 (+2.01%)
BABA   113.37 (-4.84%)
NIO   22.66 (-4.75%)
AMD   110.71 (-0.38%)
CGC   7.23 (-1.77%)
MU   81.97 (+1.55%)
GE   89.32 (-1.96%)
T   24.25 (-8.42%)
F   19.91 (-0.35%)
DIS   133.60 (-2.13%)
AMC   15.94 (-0.50%)
PFE   53.01 (+0.89%)
ACB   4.06 (-3.56%)
BA   194.27 (-4.82%)
S&P 500   4,349.93 (-0.15%)
DOW   34,168.09 (-0.38%)
QQQ   344.57 (-0.16%)
AAPL   159.69 (-0.06%)
MSFT   296.71 (+2.85%)
FB   294.63 (-1.84%)
GOOGL   2,584.66 (+1.81%)
AMZN   2,777.45 (-0.80%)
TSLA   937.41 (+2.07%)
NVDA   227.72 (+2.01%)
BABA   113.37 (-4.84%)
NIO   22.66 (-4.75%)
AMD   110.71 (-0.38%)
CGC   7.23 (-1.77%)
MU   81.97 (+1.55%)
GE   89.32 (-1.96%)
T   24.25 (-8.42%)
F   19.91 (-0.35%)
DIS   133.60 (-2.13%)
AMC   15.94 (-0.50%)
PFE   53.01 (+0.89%)
ACB   4.06 (-3.56%)
BA   194.27 (-4.82%)
NASDAQ:FENC

Fennec Pharmaceuticals Stock Forecast, Price & News

$4.64
+0.04 (+0.87%)
(As of 01/26/2022 12:00 AM ET)
Add
Compare
Today's Range
$4.46
▼
$4.82
50-Day Range
$3.89
▼
$10.01
52-Week Range
$2.90
▼
$5.20
Volume
69,245 shs
Average Volume
66,798 shs
Market Capitalization
$120.70 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.06
View Price History Chart DataSkip Price History Chart
30 days | 90 days | 365 days | Advanced Chart
Receive FENC News and Ratings via Email

Sign-up to receive the latest news and ratings for Fennec Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Fennec Pharmaceuticals logo

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.

Headlines

Fennec Pharmaceuticals Inc. Common Stock (FENC)
January 14, 2022 |  nasdaq.com
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fennec Pharmaceuticals Inc. - FENC
December 14, 2021 |  finance.yahoo.com
RTP drugmaker suffers another regulatory setback
December 1, 2021 |  finance.yahoo.com
FENC – Fennec Pharmaceuticals Inc. Investors Who Have Lost More Than $25,000 Are Encouraged To Contact Kehoe Law Firm, P.C. – Securities Class Action Investigation
November 30, 2021 |  finance.yahoo.com
Fennec Pharma: FDA Issues CRL Due To Manufacturing Deficiencies - Quick Facts
November 30, 2021 |  nasdaq.com
Fennec Shares Plunge as Pedmark Appears Headed for FDA Rejection >FENC
November 29, 2021 |  marketwatch.com
Mid-Day Market Update: Crude Oil Rises 4%; Fennec Pharmaceuticals Shares Slide
November 29, 2021 |  markets.businessinsider.com
Fennec Pharma expects FDA to decline application for hearing loss drug
November 29, 2021 |  reuters.com
Fennec does not expect U.S. approval for hearing loss drug, shares slump
November 29, 2021 |  reuters.com
Fennec Plunges As FDA Is Expected To Deny Approval For Pedmark Yet Again
November 29, 2021 |  nasdaq.com
Are Institutions Heavily Invested In Fennec Pharmaceuticals Inc.'s (NASDAQ:FENC) Shares?
November 12, 2021 |  nasdaq.com
Fennec Pharmaceuticals Announces Third Quarter 2021 Financial Results and Provides Business Update
November 10, 2021 |  finance.yahoo.com
Fennec Pharmaceuticals Announces Third Quarter 2021 Financial Results and Provides Business Update
November 10, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:FENC
Previous Symbol
CUSIP
N/A
CIK
1211583
Web
www.fennecpharma.com
Phone
919-636-4530
Fax
919-890-0490
Employees
N/A
Year Founded
N/A

Sales & Book Value

Annual Sales
$170 thousand
Price / Sales
710.03
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.12 per share
Price / Book
4.14

Profitability

EPS (Most Recent Fiscal Year)
($0.62)
Net Income
$-18.11 million
Net Margins
N/A
Pretax Margin
-9,504.12%
Return on Equity
-67.82%
Return on Assets
-57.01%

Debt

Debt-to-Equity Ratio
0.26
Current Ratio
12.90
Quick Ratio
12.90

Price-To-Earnings

Trailing P/E Ratio
N/A
Forward P/E Ratio
3.93
P/E Growth
N/A

Miscellaneous

Outstanding Shares
26,014,000
Free Float
23,496,000
Market Cap
$120.70 million
Optionable
Optionable

Company Calendar

Last Earnings
11/10/2021
Today
1/26/2022
Next Earnings (Estimated)
3/29/2022
Fiscal Year End
12/31/2022

MarketRank™

Overall MarketRank™

1.73 out of 5 stars

Medical Sector

918th out of 1,416 stocks

Biological Products, Except Diagnostic Industry

138th out of 206 stocks

Analyst Opinion: 3.4Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -












Fennec Pharmaceuticals (NASDAQ:FENC) Frequently Asked Questions

Is Fennec Pharmaceuticals a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Fennec Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Fennec Pharmaceuticals stock.
View analyst ratings for Fennec Pharmaceuticals or view top-rated stocks.

How has Fennec Pharmaceuticals' stock price been impacted by COVID-19?

Fennec Pharmaceuticals' stock was trading at $6.63 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, FENC stock has decreased by 30.0% and is now trading at $4.64.
View which stocks have been most impacted by COVID-19.

When is Fennec Pharmaceuticals' next earnings date?

Fennec Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, March 29th 2022.
View our earnings forecast for Fennec Pharmaceuticals.

How were Fennec Pharmaceuticals' earnings last quarter?

Fennec Pharmaceuticals Inc (NASDAQ:FENC) issued its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.01.
View Fennec Pharmaceuticals' earnings history.

What price target have analysts set for FENC?

5 analysts have issued 1-year target prices for Fennec Pharmaceuticals' stock. Their forecasts range from $10.00 to $14.00. On average, they anticipate Fennec Pharmaceuticals' stock price to reach $12.67 in the next year. This suggests a possible upside of 173.0% from the stock's current price.
View analysts' price targets for Fennec Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are Fennec Pharmaceuticals' key executives?

Fennec Pharmaceuticals' management team includes the following people:
  • Mr. Rostislav Raykov, Pres, CEO & Director (Age 42)
  • Mr. Robert C. Andrade, Chief Financial Officer (Age 43)
  • Mr. Mark Gowland, Controller
  • Mr. Lei Fang, Pres of Pharstat Inc
  • Ms. Anne McKay, Regulatory Consultant (Age 64)

What other stocks do shareholders of Fennec Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Fennec Pharmaceuticals investors own include Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), Pfizer (PFE), Amarin (AMRN), VBI Vaccines (VBIV), Gilead Sciences (GILD), Trevena (TRVN), Aldeyra Therapeutics (ALDX), Coherus BioSciences (CHRS) and Exelixis (EXEL).

What is Fennec Pharmaceuticals' stock symbol?

Fennec Pharmaceuticals trades on the NASDAQ under the ticker symbol "FENC."

How do I buy shares of Fennec Pharmaceuticals?

Shares of FENC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Fennec Pharmaceuticals' stock price today?

One share of FENC stock can currently be purchased for approximately $4.64.

How much money does Fennec Pharmaceuticals make?

Fennec Pharmaceuticals has a market capitalization of $120.70 million and generates $170 thousand in revenue each year. The company earns $-18.11 million in net income (profit) each year or ($0.62) on an earnings per share basis.

What is Fennec Pharmaceuticals' official website?

The official website for Fennec Pharmaceuticals is www.fennecpharma.com.

Where are Fennec Pharmaceuticals' headquarters?

Fennec Pharmaceuticals is headquartered at PO BOX 13628 68 TW ALEXANDER DRIVE, DURHAM NC, 27709.

How can I contact Fennec Pharmaceuticals?

Fennec Pharmaceuticals' mailing address is PO BOX 13628 68 TW ALEXANDER DRIVE, DURHAM NC, 27709. The company can be reached via phone at 919-636-4530 or via fax at 919-890-0490.


This page was last updated on 1/26/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.